Published in Drugs on March 01, 1995
In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother (2000) 1.65
Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. Aliment Pharmacol Ther (2014) 1.41
Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci (2007) 1.35
Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J (2005) 1.17
Prevention and self-treatment of traveler's diarrhea. Clin Microbiol Rev (2006) 1.05
In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother (2001) 1.03
Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol (2007) 1.02
The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. Dig Dis Sci (2006) 0.92
Rifaximin modulates the vaginal microbiome and metabolome in women affected by bacterial vaginosis. Antimicrob Agents Chemother (2014) 0.92
Diverticular disease of the colon: new perspectives in symptom development and treatment. World J Gastroenterol (2003) 0.89
Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol (2015) 0.87
In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea. Antimicrob Agents Chemother (2001) 0.81
Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study. Curr Ther Res Clin Exp (2004) 0.80
Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. PLoS One (2014) 0.80
Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome. Ann Clin Microbiol Antimicrob (2014) 0.78
Rifaximin in the treatment of hepatic encephalopathy. Hepat Med (2011) 0.76
Rifaximin for the treatment of acute infectious diarrhea. Therap Adv Gastroenterol (2011) 0.76
Effects of rifaximin on bacterial translocation in thioacetamide-induced liver injury in rats. Inflammation (2012) 0.76
Campylobacter concisus: a new character in the Crohn's disease story? J Clin Microbiol (2009) 0.76
Antibiotic prophylaxis in allogeneic stem cell transplantation-what is the correct choice? Bone Marrow Transplant (2016) 0.75
New treatment options for alcoholic hepatitis. World J Gastroenterol (2016) 0.75
Recent and currently emerging medical treatment options for the treatment of alcoholic hepatitis. World J Hepatol (2011) 0.75
Hyperammonemic coma in a post-partum patient with undiagnosed urea cycle defect. Indian J Crit Care Med (2013) 0.75
Management of the Cirrhotic Patient Before Liver Transplantation: The Role of the Referring Gastroenterologist. Gastroenterol Hepatol (N Y) (2006) 0.75
Utility of the Nonabsorbed (<0.4%) Antibiotic Rifaximin in Gastroenterology and Hepatology. Gastroenterol Hepatol (N Y) (2006) 0.75
Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs (1982) 3.34
Nimesulide. A preliminary review of its pharmacological properties and therapeutic efficacy in inflammation and pain states. Drugs (1988) 2.94
Midazolam. A review of its pharmacological properties and therapeutic use. Drugs (1984) 2.60
Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs (1990) 2.29
Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs (1980) 2.26
Tiaprofenic acid. A review of its pharmacological properties and therapeutic efficacy in rheumatic diseases and pain states. Drugs (1985) 2.26
Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs (1977) 2.17
Metronidazole in anaerobic infections: a review of its activity, pharmacokinetics and therapeutic use. Drugs (1978) 2.12
Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs (1983) 2.02
Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1993) 1.95
Miconazole: a review of its antifungal activity and therapeutic efficacy. Drugs (1975) 1.93
Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases. Drugs (1982) 1.87
Pyrazolone derivatives. Drugs (1986) 1.72
Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias. Drugs (1978) 1.72
Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs (1983) 1.71
Clotrimazole: a review of its antifungal activity and therapeutic efficacy. Drugs (1975) 1.69
Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs (1985) 1.69
Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis. Drugs (1980) 1.67
Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs (1984) 1.65
Amoxycillin/clavulanic acid: a review of its antibacterial activity, pharmacokinetics and therapeutic use. Drugs (1981) 1.64
Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs (1984) 1.64
Metoclopramide: a review of its pharmacological properties and clinical use. Drugs (1976) 1.63
Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. Drugs (1980) 1.59
Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs (1985) 1.56
Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia. Drugs (1981) 1.55
Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs (1997) 1.52
Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs (1984) 1.52
Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs (1977) 1.52
Nefopam: a review of its pharmacological properties and therapeutic efficacy. Drugs (1980) 1.51
Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease. Drugs (1978) 1.48
Labetalol: a review of its pharmacology and therapeutic use in hypertension. Drugs (1978) 1.44
Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs (1995) 1.43
Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs (1980) 1.43
Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs (1988) 1.41
Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea. Drugs (1978) 1.40
Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs (1994) 1.40
Minocycline: A review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs (1975) 1.38
Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs (1978) 1.37
Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs (1989) 1.35
Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy. Drugs (1981) 1.33
Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs (1979) 1.32
Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs (1993) 1.30
Cefuroxime: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs (1979) 1.29
Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs (1984) 1.26
Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs (1978) 1.23
Clobazam: a review of its pharmacological properties and therapeutic use in anxiety. Drugs (1980) 1.22
Fenoterol: a review of its pharmacological properties and therapeutic efficacy in asthma. Drugs (1978) 1.22
Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs (1982) 1.22
Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs (1975) 1.21
Sodium cromoglycate (cromolyn sodium): a review of its mode of action, pharmacology, therapeutic efficacy and use. Drugs (1974) 1.18
Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs (1987) 1.17
Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. Drugs (1983) 1.17
Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs (1987) 1.16
Carbenoxolone: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease. Drugs (1976) 1.16
Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs (1978) 1.14
Butorphanol: a review of its pharmacological properties and therapeutic efficacy. Drugs (1978) 1.13
Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs (1981) 1.13
Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs (1990) 1.12
Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs (1983) 1.12
Clonazepam: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs (1976) 1.12
Piroxicam: a review of its pharmacological properties and therapeutic efficacy. Drugs (1981) 1.11
Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs (1988) 1.11
Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs (1984) 1.11
Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs (1983) 1.11
Tri-potassium di-citrato bismuthate: a report of its pharmacological properties and therapeutic efficacy in peptic ulcer. Drugs (1976) 1.10
Diltiazem. A review of its pharmacological properties and therapeutic efficacy. Drugs (1985) 1.10
Tinidazole in anaerobic infections: a review of its antibacterial activity, pharmacological properties and therapeutic efficacy. Drugs (1982) 1.10
Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs (1990) 1.09
Nomifensine: A review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs (1979) 1.09
Sucralfate. A review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease. Drugs (1984) 1.08
Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs (1998) 1.08
Maprotiline: a review of its pharmacological properties and therapeutic efficacy in mental depressive states. Drugs (1977) 1.08
Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry. Drugs (1976) 1.08
Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging (1995) 1.07
Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs (1986) 1.06
Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs (1992) 1.04
Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs (1994) 1.04
Flurbiprofen: a review of its pharmacological properties and therapeutic use in rheumatic diseases. Drugs (1979) 1.04
Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs (1997) 1.02
Tinidazole: a review of its antiprotozoal activity and therapeutic efficacy. Drugs (1976) 1.01
Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs (1993) 1.01
Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs (1983) 1.01
Quinapril. A review of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders. Drugs (1991) 1.00
Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs (1997) 1.00
Beclomethasone dipropionate: II: Allergic rhinitis and other conditions. Drugs (1975) 1.00
Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs (1978) 1.00
Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs (1989) 0.99
Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs (1992) 0.99
Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1992) 0.98
Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs (1984) 0.98
Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs (1990) 0.98
Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs (1977) 0.97
Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs (1977) 0.97
Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs (1984) 0.96
Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Drugs (1996) 0.96